NOS2 (Inducible Nitric Oxide Synthase) produces nitric oxide in response to inflammatory stimuli. It plays a complex role in neuroinflammation and has been implicated in the pathogenesis of various neurodegenerative diseases including Alzheimer's and Parkinson's.
Structure
NOS2 is a homodimeric enzyme, with each monomer comprising multiple functional domains:
N-terminal oxygenase domain (1-498 aa): Contains the catalytic site with binding sites for heme, tetrahydrobiopterin (BH4), L-arginine, and the substrate
Calmodulin-binding domain (500-532 aa): Binds calcium-calmodulin for enzyme activation
C-terminal reductase domain (533-1153 aa): Contains FAD and FMN, transfers electrons from NADPH to the oxygenase domain
The enzyme requires multiple cofactors:
Heme (protoporphyrin IX)
Tetrahydrobiopterin (BH4)
FAD and FMN
Calmodulin (calcium-dependent binding)
Normal Function in the Nervous System
Nitric oxide (NO) produced by NOS2 serves as a signaling molecule in the nervous system:
Neurotransmission: NO acts as a retrograde neurotransmitter, modulating synaptic plasticity, learning, and memory
Blood flow regulation: NO produced by endothelial NOS (NOS3) and NOS2 regulates cerebral blood flow
Neuroprotection: Low levels of NO have neuroprotective effects through antioxidant gene activation
Developmental roles: NO guides axonal pathfinding and participates in synaptic formation
Immune surveillance: In glial cells, NOS2 produces NO as part of the innate immune response
Role in Disease
Alzheimer's Disease
NOS2 plays a complex, context-dependent role in AD:
Chronic neuroinflammation: Aβ plaques and tangles activate [microglia](/cell-types/microglia-neuroinflammation) and [astrocytes](/entities/astrocytes), inducing NOS2 expression
Nitrosative stress: Excessive NO production leads to protein nitration, lipid peroxidation, and DNA damage
NO signaling impairment: Reduced NO bioavailability impairs cerebral blood flow and synaptic plasticity
[Tau](/proteins/tau) nitration: NO contributes to tau pathology through nitrosylation reactions
Therapeutic targeting: NOS2 inhibitors have shown promise in preclinical AD models
Parkinson's Disease
Dopaminergic neuron vulnerability: NOS2 expression in microglia contributes to dopaminergic neuron death
Neuroinflammation: MPTP and [α-synuclein](/proteins/alpha-synuclein) aggregation activate NOS2 in glial cells
Mitochondrial dysfunction: NO inhibits mitochondrial respiration and promotes mitochondrial permeability transition
Amyotrophic Lateral Sclerosis
Motor neuron injury: Activated microglia and astrocytes produce NO through NOS2
Oxidative stress: Peroxynitrite (ONOO⁻) formed from NO and superoxide causes protein nitration
Disease progression: NOS2 expression correlates with disease severity in ALS models
Multiple Sclerosis
Demyelination: NO produced by NOS2 in immune cells contributes to oligodendrocyte death
Axonal injury: Nitrosative stress damages axons in MS lesions
[Blood-brain barrier](/entities/blood-brain-barrier) disruption: NO increases vascular permeability
Stroke and Ischemia
Ischemic injury: NOS2 is upregulated after stroke, contributing to excitotoxic damage
Therapeutic window: Early NOS2 inhibition may be neuroprotective; late inhibition may be detrimental
Therapeutic Targeting
Key Publications
[Heneka et al., NOS2 in neurodegenerative disease (2015)](https://doi.org/10.1016/j.neuropharm.2014.09.028)
[Steinert et al., Nitric oxide and neurodegeneration (2022)](https://doi.org/10.1016/j.tins.2022.03.004)
[Lawson et al., Microglial NOS2 in AD and PD (2020)](https://doi.org/10.1016/j.neuropharm.2020.108194)
[Guix et al., NO signaling in synaptic plasticity (2021)](https://doi.org/10.1152/jn.00114.2021)
[Brown, Targeting NOS2 for neuroprotection (2019)](https://doi.org/10.1016/j.pharmthera.2019.107412)
[Chabrashvili et al., NOS2 in ALS (2021)](https://doi.org/10.1007/s12035-021-02293-1)
This page was created as part of the NeuroWiki protein page initiative for neurodegeneration research.
Role in Neurodegeneration
NOS2/iNOS plays a complex role in neurodegeneration:
Neuroinflammation: Activated microglia and astrocytes express NOS2 in response to inflammatory stimuli, producing high levels of NO that can be neurotoxic
Oxidative stress: NO reacts with superoxide to form peroxynitrite (ONOO-), a potent oxidant that damages proteins, lipids, and DNA
Alzheimer's disease: Elevated NOS2 expression is observed in AD brains, contributing to [amyloid-beta](/proteins/amyloid-beta) toxicity and tau pathology
Parkinson's disease: NOS2 is upregulated in PD models and may contribute to dopaminergic neuron death
ALS: Increased NOS2 expression in motor [neurons](/entities/neurons) and microglia
Therapeutic Implications
Targeting NOS2 for neuroprotection:
Selective iNOS inhibitors: Being developed for inflammatory and neurodegenerative conditions
NO scavengers: Trap excess NO to prevent nitrosative stress
[Calabrese V, Mancuso C, Calvani M, et al, Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity (2007)](https://pubmed.ncbi.nlm.nih.gov/17882254/)
Stone JR, Marletta MA, Spectral and kinetic studies on the activation of soluble guanylate cyclase by nitric oxide (1998)